Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | SYK | P43405 | 14/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594440 | 0.87 | MAOB (0.49) | APPSYKMAOAMAOB | |
| SCHEMBL3581475 | 0.86 | SYK (0.48) | APPSYKEGFRMAOBKMT2A | |
| SCHEMBL14753418 | 0.86 | NPC1 (0.48) | APPSYKKMT2A | |
| SCHEMBL3592355 | 0.85 | SYK (0.52) | APPSYKEGFRKMT2A | |
| SCHEMBL3600524 | 0.78 | APP (0.62) | APPSYKMAOB | |
| SCHEMBL3607808 | 0.77 | APP (0.72) | APPSYKEGFRKMT2A | |
| SCHEMBL3594431 | 0.74 | APP (0.61) | APPSYKKMT2APKMYT1 | |
| SCHEMBL656182 | 0.74 | SYK (0.74) | SYKEGFR | |
| SCHEMBL653987 | 0.74 | SYK (0.74) | SYKEGFRPKMYT1 | |
| SCHEMBL3602388 | 0.74 | APP (1.00) | APPSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HORWELL DAVID CHRISTOPHER (GB) | 2013-03-07 | — | — | US | disclosed |
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HORWELL DAVID CHRISTOPHER (GB) | 2013-03-07 | — | — | US | disclosed |
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HORWELL DAVID CHRISTOPHER (GB) | 2013-03-07 | — | — | US | disclosed |
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-2010502-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | Senexis Limited (GB) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007125351-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | TYMP, APP, HTT | APP 2/4885SYK 3311/4885EGFR 4293/4885 |
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | TYMP, APP, HTT | APP 2/4885SYK 3311/4885EGFR 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.